Indivior Pharmaceuticals (INDV) Accumulated Expenses (2023 - 2026)

Indivior Pharmaceuticals' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 86.67% year-over-year to $14.0 million in Q1 2026; TTM through Mar 2026 was $14.0 million, a 86.67% decrease from a year earlier, with the FY2025 full-year figure at $42.0 million, down 57.58% from the prior year.
• Accumulated Expenses declined to $14.0 million in Q1 2026 per INDV's latest filing, from $42.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $492.0 million in Q4 2023 and bottomed at $14.0 million in Q1 2026.
• The 4-year median for Accumulated Expenses is $105.0 million (2025), against an average of $137.6 million.
• Across the five-year window, Accumulated Expenses plunged 57.58% in 2025 and sank 86.67% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $492.0 million in 2023, then sank by 79.88% to $99.0 million in 2024, then plunged by 57.58% to $42.0 million in 2025, then sank by 66.67% to $14.0 million in 2026.
• Per Business Quant, the three latest INDV Accumulated Expenses figures stand at $14.0 million (Q1 2026), $42.0 million (Q4 2025), and $106.0 million (Q3 2025).